Evidence map›Paper›PMID 27599854›Full record

ArticleActa crystallographica. Section F, Structural biology communications2016

Crystal structure of Plasmodium falciparum proplasmepsin IV: the plasticity of proplasmepsins.

Rosario Recacha, Kristaps Jaudzems, Inara Akopjana, Aigars Jirgensons, Kaspars Tars

Open access · bronzeAbstract read
In one paragraph

Article in Acta crystallographica. Section F, Structural biology communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Rosario RecachaLatvian Institute of Organic Synthesis, Aizkraukles 21, Riga, LV-1006, Latvia.
Kristaps JaudzemsLatvian Institute of Organic Synthesis, Aizkraukles 21, Riga, LV-1006, Latvia.
Inara AkopjanaBiomedical Research and Study Centre, Ratsupites 1, Riga, LV-1067, Latvia.
Aigars JirgensonsLatvian Institute of Organic Synthesis, Aizkraukles 21, Riga, LV-1006, Latvia.
Kaspars TarsBiomedical Research and Study Centre, Ratsupites 1, Riga, LV-1067, Latvia.
Latvian Biomedical Research and Study Centre · LVHelmholtz-Zentrum Berlin für Materialien und Energie · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasmepsin IV from Plasmodium falciparum (PM IV) is a promising target for the development of novel antimalarial drugs. Here, the crystal structure of the truncated zymogen of PM IV (pPM IV), consisting of the mature enzyme plus a prosegment of 47 residues, has been determined at 1.5 Å resolution. pPM IV presents the fold previously described for studied proplasmepsins, displaying closer similarities to proplasmepin IV from P. vivax (pPvPM) than to the other two proplasmepsins from P. falciparum. The study and comparison of the pPM IV structure with the proplasmepsin structures described previously provide information about the similarities and differences in the inactivation-activation mechanisms among the plasmepsin zymogens.

Indexed as

Amino Acid SequenceAspartic Acid EndopeptidasesBinding SitesCloning, MolecularCrystallography, X-RayEnzyme PrecursorsEscherichia coliGene ExpressionIsoenzymesModels, MolecularPlasmidsPlasmodium falciparumProtein BindingProtein Conformation, alpha-HelicalProtein Conformation, beta-StrandProtein Interaction Domains and MotifsAspartic Acid EndopeptidasesEnzyme PrecursorsIsoenzymesplasmepsinProtozoan ProteinsRecombinant Proteinsaspartic protease zymogenmalariaPlasmodium falciparumproplasmepsin IV

Identifiers

PMID27599854
PMCPMC5012203
OpenAlexW2507166699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.